3632 results for «231»
3632 results
Monotherapy vs. DAPT: striking the balance between ischemia and bleeding
20 May 2026 – From EuroPCR 2026
This session examines the balance between ischemic and bleeding risks by comparing monotherapy regimens and dual antiplatelet therapy (DAPT) following PCI. Key topics include clopidogrel versus aspirin monotherapy, aspirin discontinuation timing after ACS, and the impact of P2Y12 adherence on clinical outcomes in high-risk and oral...
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
Safe management of assisted PCI : what can go wrong
20 May 2026 – From EuroPCR 2026
Explore the complexities and potential complications associated with assisted PCI in this session. Topics include challenges such as microaxial pump kinks, technical aspects of IMPELLA device deployment, and the management of high-risk PCI cases including patients with prior TAVI, highlighting strategies to mitigate risks during protected...
Complex endovascular and pulmonary interventions
20 May 2026 – From EuroPCR 2026
Explore advances in complex endovascular and pulmonary interventions, including the transformation of interventional labs into intelligent learning ecosystems, innovative approaches to peripheral and coronary CTOs, and novel therapies such as extravascular renal denervation and fixation catheters for acute pulmonary embolism.
Imaging guided ultralow contrast PCI
20 May 2026 – From EuroPCR 2026
This session focuses on imaging-guided ultralow contrast PCI techniques designed to minimize contrast-induced nephropathy risk. It includes IVUS-guided strategies for distal left main bifurcation PCI, zero-contrast interventions in renal transplant patients, and precision stent placement without contrast use, emphasizing safety, precision, and frugality in contemporary PCI...
What bench testing teaches us about real world PCI
19 May 2026 – From EuroPCR 2026
This session explores bench testing insights into real-world percutaneous coronary interventions (PCI). Topics include comparative expansion ratios of coronary stents, prognostic assessments after drug-coated balloon treatments, mechanical performance of magnesium scaffolds in bifurcations, preclinical safety and computational modeling of bioresorbable polymer-coated stents, and evaluations of commonly...
Assessment of vasomotor coronary disorders in the cathlab
20 May 2026 – From EuroPCR 2026
This session focuses on the invasive assessment of vasomotor coronary disorders within the catheterization laboratory. It reviews clinical profiles, endothelial function evaluation using acetylcholine and advanced hemodynamic methods, coronary volume analysis, and refined classification of coronary spasm, enhancing diagnostic accuracy in patients with suspected ischemia and...
Lost, crushed, fractured: stent complications in real life
20 May 2026 – From EuroPCR 2026
This session addresses real-world challenges of stent complications including loss, crushing, and fracture during PCI. Through case-based discussions, it explores complex scenarios such as stent dislodgement, embolisation, and management strategies when initial plans evolve into complicated realities.
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
